Open AccessFactors Associated With Delayed Hepatitis B Viral Suppression on Tenofovir Among Patients Coinfected With HBV-HIV in the CNICS Cohort
Author(s) -
H. Nina Kim,
Carla V. Rodriguez,
Stephen Van Rompaey,
Joseph J. Eron,
Chloe L. Thio,
Heidi M. Crane,
Edgar Turner Overton,
Michael S. Saag,
Jeffrey N. Martin,
Elvin Geng,
Michael J. Mugavero,
Benigno Rodríguez,
W. Christopher Mathews,
Stephen Boswell,
Richard Moore,
Mari M. Kitahata
Publication year - 2014
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000000126
Subject(s) - medicine , emtricitabine , hepatitis b virus , lamivudine , cohort , interquartile range , hepatitis b , regimen , viral load , immunology , virology , gastroenterology , human immunodeficiency virus (hiv) , virus
Despite widespread use in HIV and hepatitis B virus (HBV) infection, the effectiveness of tenofovir (TDF) has not been studied extensively outside of small cohorts of coinfected patients with HBV-HIV. We examined the effect of prior lamivudine (3TC) treatment and other factors on HBV DNA suppression with TDF in a multisite clinical cohort of coinfected patients.